Antares Pharma Inc

Antares Pharma — UBS Global Life Sciences Conference 2004

31 slides from Antares Pharma's conference presentation, Sep 28, 2004

  1. Slide 1: Antares Pharma, Inc.

    Antares Pharma, Inc. Amex: AIS www.antarespharma.com UBS Global Life Sciences Conference September 28, 2004

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements which are not s

  3. Slide 3: Agenda

    Agenda Overview Products, Platforms and Pipelines Alliances, Partnerships and Markets Financial Overview Summary

  4. Slide 4: Overview

    Overview 4e antares a

  5. Slide 5: Antares Pharma Positioning

    Antares Pharma Positioning Antares Pharma, Inc., is uniquely positioned as an emerging specialty pharmaceutical company focused on leveraging its global product pipeline and drug delivery platforms to be commercially focused on creating and improving value-added products and systems of drugs and dru

  6. Slide 6: Antares Pharma Business Model

    Antares Pharma Business Model “Taking Control of Our Own Destiny” “Guerilla” market approved products (VISION®, ibuprofen) Advance products to the latest development stage possible: – Niche products in key therapeutic areas of women’s health, pain, CNS – Partner more complex products or costly progr

  7. Slide 7: Recent History & Milestones

    Recent History & Milestones Formed January 2001 by business combination of Permatec and Medi-Ject Headquarters in Exton, PA; Operations in Minneapolis and Basel Founder and Chairman, Dr. Jacques Gonella Launched Medi-Jector VISION® in 1999; today the leader in needle-free September 2003: Announced w

  8. Slide 8: Products, Platforms and Pipelines

    Products, Platforms and Pipelines

  9. Slide 9: Technology Platforms

    Technology Platforms Transdermal Drug Delivery-ATD™Gels Systemic Transdermal Gel Technology (ATD™) ATD™ Single Gels ATD™ Combination Gels Local Topical Delivery Technology Fast Melting Tablets Easy Tec™ Injection Devices Mini-Needle Disposable Injectors (AJ Platform) Vibex™ Needle-Free Reusable Inje

  10. Slide 10: Transdermal Drug Delivery: ATD Gels

    Transdermal Drug Delivery: ATD™ Gels (Advanced Transdermal Delivery) Patented gel formulation technology Creates sub-dermal reservoir of drug for systemic delivery over 24 hours More than 15 years of scientific experience in gel technology Successfully developed and partnered several hormone-based A

  11. Slide 11: Fast-Melt Tablets – Easy Tec

    Fast-Melt Tablets – Easy Tec™ Patented oral tablet Disintegrates and dissolves rapidly in saliva Ease of manufacture, packaging tech transfer and time to market Important for patients who have difficulty swallowing Therapeutic areas include pain, Alzheimer’s, analgesics, CNS 2002 sector revenues > $

  12. Slide 12: Injection Devices: Disposable Mini-Needle Injectors

    Injection Devices: Disposable Mini-Needle Injectors Vibex™ (AJ platform) Single use, prefilled and disposable Mini-needle always hidden Standard Hypak prefilled syringe or prefilled containers General disposal Can deliver variable doses Cost effective Provides competitive advantage Negotiating exclu

  13. Slide 13: Injection Devices: Reusable Needle-Free Technology

    Injection Devices: Reusable Needle-Free Technology (Vision™MJ Platform) VISION® marketed since 1999 for insulin and hGH Uses spring to pressurize liquid drug and force it through very small orifice Thin column of fluid penetrates skin and deposited in subcutaneous tissue Targeted to growing protein

  14. Slide 14: Partnered Formulation (Transdermal) Products

    Corporate Partnered Formulation (Transdermal) Products Formulation Development Preclinical Testing Clinical Phase I/II Clinical Phase III Regulatory Submission Commercialization License Status Ibuprofen Gel (pain, inflammation) Available N.A., Asia Pacific parts EU Estradiol Patch Licensed in (hormo

  15. Slide 15: Device Products

    Device Products Concept Prototype for Design Manufacturing Regulatory Commercialization Clinical Finalization Scale-Up Submission Evaluation VisionRfor Insulin (needle-free injector) Antares Pharma-in market VisionRfor hGH (needle-free injector) Ferring-Europe, U.S.; JCR - Japan - launch late 2004 S

  16. Slide 16: Specialty Pharma Products

    Specialty Pharma Products Formulation Preclinical Clinical Phase III (where necessary) Regulatory Commercialization Development Testing Phase I / II necessary) Submission Oxybutynin ATDTM gel (urinary incontinence) Gel Product 1 ATDTM *Estradiol ATDTM gel (hormone therapy) *Testosterone ATDTM gel (f

  17. Slide 17: Alliances, Partnerships and Markets

    Alliances, Partnerships and Markets

  18. Slide 18: Established Corporate Partners

    Established Corporate Partners

  19. Slide 19: Insulin Injection Opportunity

    Insulin Injection Opportunity Progress recognized with milestone payment in December Worldwide 150m with diabetes (growing to 300m by 2025); approximately 10-12m insulin users worldwide 17m patients with diabetes in the US; 4m taking insulin Lilly insulin sales in 2002: $1.8b.Lilly U.S. market share

  20. Slide 20: Estimated Needle-Free Injection Sales

    Estimated Needle-Free Injection Sales (in Millions) 450 400 350 300 250 200 150 50 0 $10.3 $425 $195 $230 all other 46% Insulin 54% 2002 2007 Source: Greystone Associates, Needle-free Injection, June 2003

  21. Slide 21: Transdermal Testosterone Gel for Women Opportunity

    Transdermal Testosterone Gel for Women (Female Sexual Dysfunction) Opportunity Currently no Rx product available to treat FSD 43% prevalence of sexual dysfunction in females versus 31% in males Modest estimate of U.S.market potential of $2.0 billion; other estimates as much as $4.0 billion Several d

  22. Slide 22: Results of Phase II Study for Testosterone Gel for Women

    Results of Phase II Study for Testosterone Gel for Women Announced September 22, 2004: Results from double-blind, placebo-controlled Phase II study with LibiGel™ were released Conducted in the U.S. with 46 hysterectomized women with low sexual desire and activity No serious adverse events and no dis

  23. Slide 23: Oxybutynin Gel for Treatment of Overactive Bladder Syndrome

    Oxybutynin Gel for Treatment of Overactive Bladder Syndrome OBS estimated to affect 16 -18% of adults in U.S. (19m) and Europe with higher percentages reported in Asia Products currently used have side effects such as dry mouth (23-24%), dry eyes, blurred vision and constipation Market estimated to

  24. Slide 24: Transdermal Delivery Market

    Transdermal Delivery Market US$ (Billions) 14 12 10 8 6 4 2 0 $8.0 $12.7 2002 2005 Source: Jain PharmaBiotech –November 2002

  25. Slide 25: Financial Overview

    Financial Overview 4e antares a

  26. Slide 26: Gross Revenues

    Gross Revenues $ Millions 6 5 4 3 2 1 0 2001 2002 2003 Product Sales Development Fees Licensing Milestones Total Revenues

  27. Slide 27: Antares Pharma Financial Summary as of June 30, 2004

    Antares Pharma – Financial Summary as of June 30, 2004 2004 YTD gross revenues $1.4m Cash & cash equivalents $13.15m Shares outstanding 38m Fully diluted shares outstanding 62m Debt None Market cap at 09-24-2004 $60.3 52 week share price range (at 09-24-2004) $.60—$2.01

  28. Slide 28: Antares Pharma Share Volume Moving Average Year to Date

    Antares Pharma – Share Volume Moving Average Year to Date 900,000 800,000 700,000 600,000 500,000 400,000 300,000 200,000 100,000 0 10 Day Moving Ave 30 Day Moving Ave Jan-04 Jan-04 Jan-04 Jan-04 Jan-04 Feb-04 Feb-04 Feb-04 Feb-04 Mar-04 Mar-04 Mar-04 Mar-04 Apr-04 Apr-04 Apr-04 Apr-04 Apr-04 May-04

  29. Slide 29: Antares Pharma Share Price Moving Average Year to Date

    Antares Pharma – Share Price Moving Average Year to Date 1.600 1.400 1.200 1.000 0.800 0.600 0.400 0.200 0.000 10 Day Moving Ave 30 Day Moving Ave Jan-04 Jan-04 Jan-04 Feb-04 Feb-04 Mar-04 Mar-04 Apr-04 Apr-04 May-04 May-04 Jun-04 Jun-04 Jul-04 Jul-04 Jul-04 Aug-04 Aug-04 Sep-04 Sep-04

  30. Slide 30: Summary and Investment Rationale

    Summary and Investment Rationale Antares Pharma is an emerging specialty pharma company with: A global vision and opportunity including a major international presence A broad array of synergistic platforms to exploit Established alliances and partnerships with big and specialty pharma Significant op

  31. Slide 31: Thank you

    Drugs don’t work if people don’t take them—C. Everett koop Thank you

Antares Pharma — UBS Global Life Sciences Conference 2004 on 6ix